Abstract: A method for detecting a manipulated or falsified GNSS signal is disclosed The method includes a) receiving a GNSS signal; b) analyzing the GNSS signal in order to determine at least one signal property and at least one satellite property from the GNSS signal; c) comparing the determined at least one signal property with at least one known signal property which is determined as a function of the detected at least one satellite property; and d) detecting a manipulated or falsified GNSS signal if there is a discrepancy between the determined signal property and the known signal property.

Abstract: Pharmaceutical compositions that include a poorly water-soluble therapeutic compound, an aqueous solvent, an chelator/antioxidant, a buffer or buffer component, and a bulking agent. The pharmaceutical compositions can be orally ingested or administered parenterally. The pharmaceutical compositions can further be lyophilized to form a pharmaceutically acceptable cake that can be administered orally, e.g., as a solid oral dosage form; or reconstituted and administered parenterally, e.g. as a single i.v. bolus or iv infusion, or administered orally, e.g. as a drink solution.

Abstract: The invention relates to a lyophilised pharmaceutical preparation comprising an antibody against the endothelial growth factor receptor (EGF receptor). The preparation has increased storage stability, even at elevated temperatures, and, after reconstitution, can be used parenterally for the treatment of tumours.

Abstract: The present invention relates to an aqueous pharmaceutical preparation of oligopeptides comprising an oligopeptide of the formula I, cyclo-(n-Arg-nGly-nAsp-nD-nE), and a partially etherified ?-cyclodextrin having a water solubility of greater than 1.8 mg/ml of water, and to the preparation of the aqueous pharmaceutical preparation.

Abstract: The present invention relates to an aqueous pharmaceutical preparation of oligopeptides comprising an oligopeptide of the formula I, cyclo-(n-Arg-nGly-nAsp-nD-nE), and a partially etherified ?-cyclodextrin having a water solubility of greater than 1.8 mg/ml of water, and to the preparation of the aqueous pharmaceutical preparation.

Abstract: The invention relates to a lyophilised pharmaceutical preparation comprising an antibody against the endothelial growth factor receptor (EGF receptor). The preparation has increased storage stability, even at elevated temperatures, and, after reconstitution, can be used parenterally for the treatment of tumours.

Abstract: The invention relates to a lyophilised pharmaceutical preparation comprising an immunocytokine. The preparation has an increased shelf life, even at elevated temperatures, and, after reconstitution, can be administered parenterally as a medicament.

Abstract: The medicament in particulate form has one or more anionic or partially anionic active substances bound to a carrier material. The carrier material includes particulate copolymer or homopolymer of acrylic acid or acrylic acid ester or methacrylic acid esters. The carrier further includes oxygen in the ester group, a branched or unbranched alkyl chain with 2-10 carbon atoms, --NR.sub.2 where R represents H and lower alkyl chains in any combination, and H or a lower alkyl chain. The grain size distribution of the carrier is 10-1000 nm.